Want to see KR:271980 full AI Analyst Report?
Top Page
Jeil Pharmaceutical Co. Ltd.
(271980)
Select Model
Select Model
Rating:53Neutral
Price Target:
₩8,932.00
Action:N/A
Date:10/28/26
The score is driven primarily by mixed financial performance: profitability has recovered and leverage is manageable, but cash flow quality is weak with negative free cash flow and inconsistent operating cash generation. Technical indicators are notably bearish with the stock trading below major moving averages and negative momentum, partially offset by a low P/E that suggests relatively attractive valuation.
Positive Factors
Profitability Recovery
The return to positive TTM net income indicates that the business has regained earnings capacity after several loss-making years. This improves internal funding potential and provides a stronger base for sustaining operations, investing in products, and rebuilding shareholder returns over the next several quarters.
Negative Factors
Weak Cash Conversion
Persistent negative free cash flow and repeated years of negative operating cash flow indicate that accounting earnings have not consistently translated into available cash. This can constrain investment and debt-management capacity, while increasing liquidity pressure if operating conditions weaken again.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Recovery
The return to positive TTM net income indicates that the business has regained earnings capacity after several loss-making years. This improves internal funding potential and provides a stronger base for sustaining operations, investing in products, and rebuilding shareholder returns over the next several quarters.
Read all positive factors
Jeil Pharmaceutical Co. Ltd. (271980) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩125.32B
Dividend Yield0.3%
Average Volume (3M)15.83K
Price to Earnings (P/E)7.1
Beta (1Y)0.19
Revenue Growth-17.85%
EPS Growth81.91%
CountryKR
Employees1,011
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1215.67
Shares Outstanding14,704,872
10 Day Avg. Volume18,386
30 Day Avg. Volume15,828
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.06
Price to Sales (P/S)0.39
P/FCF Ratio-16.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jeil Pharmaceutical Co. Ltd. Business Overview & Revenue Model
Company Description
Primarily active within South Korea, Jeil Pharmaceutical Co.,Ltd dedicates itself to the development and supply of a broad spectrum of pharmaceutical goods. Its product offerings address numerous therapeutic categories, including antibiotics, gast...
Jeil Pharmaceutical Co. Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
64
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 543.49B | 566.34B | 704.54B | 726.39B | 722.23B | 700.69B |
| Gross Profit | 212.37B | 208.38B | 177.49B | 184.26B | 156.80B | 155.98B |
| EBITDA | 24.82B | 32.65B | -10.61B | 17.72B | -1.21B | -2.02B |
| Net Income | 9.32B | 23.38B | -29.97B | 5.00B | -13.09B | -12.47B |
Balance Sheet | ||||||
| Total Assets | 526.12B | 510.57B | 525.70B | 487.33B | 456.89B | 426.49B |
| Cash, Cash Equivalents and Short-Term Investments | 67.41B | 58.83B | 57.46B | 35.66B | 31.59B | 28.00B |
| Total Debt | 112.28B | 93.42B | 75.70B | 71.17B | 50.35B | 47.80B |
| Total Liabilities | 272.85B | 259.55B | 306.38B | 330.29B | 301.29B | 259.14B |
| Stockholders Equity | 205.81B | 211.07B | 188.15B | 158.57B | 157.91B | 168.21B |
Cash Flow | ||||||
| Free Cash Flow | -5.84B | -13.72B | -3.40B | -14.56B | -32.11B | 13.71B |
| Operating Cash Flow | 7.85B | -5.69B | 3.21B | -4.98B | -15.15B | 19.10B |
| Investing Cash Flow | -19.91B | -15.34B | -7.30B | -11.92B | -12.92B | -8.04B |
| Financing Cash Flow | 20.53B | 17.05B | 23.06B | 18.77B | 33.62B | 11.07B |
Jeil Pharmaceutical Co. Ltd. Technical Analysis
Negative
―
Price Trends
9903.40
Negative
9996.40
Negative
12039.20
Negative
Market Momentum
-353.01
Positive
20.06
Positive
12.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:271980, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 9465.50, equal to the 50-day MA of 9903.40, and equal to the 200-day MA of 12039.20, indicating a bearish trend. The MACD of -353.01 indicates Positive momentum. The RSI at 20.06 is Positive, neither overbought nor oversold. The STOCH value of 12.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:271980.
Jeil Pharmaceutical Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ₩141.36B | 7.82 | ― | 4.80% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₩125.32B | 7.07 | ― | 0.30% | -17.85% | 81.91% | |
50 Neutral | ₩189.25B | 70.81 | ― | 2.88% | 1.83% | -67.89% | |
49 Neutral | ₩122.88B | 24.71 | ― | 0.97% | 10.51% | -51.40% | |
47 Neutral | ₩164.86B | -4.34 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩113.23B | -0.83 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:271980
Jeil Pharmaceutical Co. Ltd.
8,600.00
-5,780.00
-40.19%
KR:000020
Dong Wha Pharm Co., Ltd.
5,100.00
-1,090.56
-17.62%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,650.00
-1,850.00
-19.47%
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,203.00
-330.00
-21.53%
KR:003220
Daewon Pharmaceutical Co., Ltd
8,680.00
-4,063.18
-31.89%
KR:214390
Kyongbo Pharmaceutical Co., Ltd.
5,140.00
-709.14
-12.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.